 |  |  |  |  |  |  |  |
| The Pan-Asian Network for Neglected Disease PAN4ND |
| Previous Meetings 29 Nov-1 Dec 2007 Malaysia Mtg materials Presentations |
P
A
N
4
N
D
A
N
4
N
D
PAN4ND's Mission
The PAN4ND network serves to encourage research collaboration between member
institutions to maximize the potential for discovery of hits and leads from Natural
Products for development as drugs for Neglected Diseases.
The PAN4ND network serves to encourage research collaboration between member
institutions to maximize the potential for discovery of hits and leads from Natural
Products for development as drugs for Neglected Diseases.
Coordinator of network: DNDi
The network is coordinated by the Drugs for Neglected Diseases Initiative (DNDi), a
not-for-profit drug development partnership based in Geneva.
Founded in 2003 to address the needs of patients with the most neglected diseases,
DNDi works to research, develop, and facilitate the availability of new and improved
treatments against sleeping sickness (human African trypanosomiasis, HAT), visceral
leishmaniasis (VL), Chagas disease, and malaria.
DNDi has developed the largest ever R&D portfolio for the kinetoplastid diseases and
has already released two new antimalarial medicines. DNDi also raises awareness
about the need for greater R&D for neglected diseases, advocates for public
prioritization of neglected diseases, and strengthens existing research capacity in
disease-endemic countries.
Managing projects with both private and public partners, DNDi uses a "needs-driven"
portfolio-based approach that facilitates basic science, preclinical, and clinical
research on targeted diseases.
To learn more, visit www.dndi.org.
With industrial partners, DNDi has now made two new fixed-dose antimalarial
combinations available. Visit www.actwithasaq.org and www.actwithasmq.org.
The network is coordinated by the Drugs for Neglected Diseases Initiative (DNDi), a
not-for-profit drug development partnership based in Geneva.
Founded in 2003 to address the needs of patients with the most neglected diseases,
DNDi works to research, develop, and facilitate the availability of new and improved
treatments against sleeping sickness (human African trypanosomiasis, HAT), visceral
leishmaniasis (VL), Chagas disease, and malaria.
DNDi has developed the largest ever R&D portfolio for the kinetoplastid diseases and
has already released two new antimalarial medicines. DNDi also raises awareness
about the need for greater R&D for neglected diseases, advocates for public
prioritization of neglected diseases, and strengthens existing research capacity in
disease-endemic countries.
Managing projects with both private and public partners, DNDi uses a "needs-driven"
portfolio-based approach that facilitates basic science, preclinical, and clinical
research on targeted diseases.
To learn more, visit www.dndi.org.
With industrial partners, DNDi has now made two new fixed-dose antimalarial
combinations available. Visit www.actwithasaq.org and www.actwithasmq.org.
PAN4ND's Primary Objectives
- To link Natural Products
researchers and institutes as
a collaborative network
- To incorporate Neglected
Diseases into our drug
candidate screening programs
- To standardize network
screening methodologies
against Parasitic Targets and
other pathogens
| How PAN4ND works |
Who Funds Us?
The Sasakawa Peace Foundation has provided and continues to provide the
funding necessary for the creation and upkeep of PAN4ND.
The Sasakawa Peace Foundation has provided and continues to provide the
funding necessary for the creation and upkeep of PAN4ND.
| Leading regional researchers recently met during at the 3rd Annual PASN Meeting in Tokyo, Japan Learn more... Read Yakujinippo article. |
A Manual on Drug Screening for Kinetoplastids PDF now available online. |
